Compare BioNTech SE - ADR (BNTX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.56. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SPXL | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $296.39 |
52-Week Low | $83.89 | $170.20 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.
Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
